Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM.
Sasaki K, et al. Among authors: kantarjian hm.
Cancer. 2016 Dec 1;122(23):3650-3656. doi: 10.1002/cncr.30231. Epub 2016 Aug 1.
Cancer. 2016.
PMID: 27479888
Free PMC article.
Clinical Trial.